Hereditary gynaecological cancer is characterized by its incidence in individuals younger than 40 yearsold. In women, it accounts for between 5-15% of cases of this type of cancer. The origin of this genetic susceptibility often consists of mutations in the BRCA1 and BRCA2 genes, although there are other genes related to breast, ovarian and endometrial cancer that should be studied to provide more complete information for a more comprehensive medical analysis.

The BRCA + is an analysis of the patient DNA by Next Generation Sequencing (NGS), to detect point mutations and small insertions/deletions in 18 genes (ATM, BRCA 1, BRCA 1, BRIP 1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53) related to hereditary gynaecological cancer. Additionally, the MLPA (Multiple Ligation Probe Amplification) technique of the BRCA1, BRCA2 and EPCAM genes is performed for the detection of large deletions and duplications.

• Women older than 30 yearsoldwithout family history, as a preventive measure to breast and/or ovary cancer.
• Women with a family history of breast cancer (male or female) and/or ovary cancer.
• Relative carrier of a mutation in BRCA1 or BRCA2.
• Patients suffering from this type of tumor, in order to determine theirpossible hereditary profile.

Next generation sequencing (NGS) and  Multiple Ligation Probe Amplification (MLPA)